Gilead Sciences, Inc. — GILD
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $148.95 | $184.80B | 21.9 | 15.4 | 12.1% | 8.4% | $3.28 2.2% | 8.1 |
Latest Headlines
- · Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
- · Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
- · Kymera Therapeutics Q4 Earnings Call Highlights
- · Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...
- · Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
- · Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $24,689M | $123M | $0.10 | 2024-02-09 04:07:05 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $27,281M | $4,592M | $4.96 | 2026-02-27 21:58:03 | 10.5% | 3633.3% | 4860.0% |
| 2 | 2022-12-31 | $27,281M | $4,592M | $3.66 | 2026-02-27 21:58:03 | 0.0% | 0.0% | -26.2% |
| 3 | 2023-12-31 | $27,116M | $5,665M | $4.54 | 2026-02-27 21:58:03 | -0.6% | 23.4% | 24.0% |
| 4 | 2024-12-31 | $28,754M | $480M | $0.38 | 2026-02-27 21:58:03 | 6.0% | -91.5% | -91.6% |
| 5 | 2025-12-31 | $29,442M | $8,510M | $0.38 | 2026-02-27 21:58:03 | 2.4% | 1672.9% | 0.0% |
| 6 | TTM 2025-12-31 | $29,441M | $8,510M | $6.79 | 2026-02-12 08:39:26 | -0.0% | 0.0% | 1686.8% |
EPS
Forecasts
Y/Y % Change
GILD Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 10.5% | 0.0% | -0.6% | 6.0% | 2.4% | 2.4% | 7.4% | 4.0% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | 3633.3% | 0.0% | 23.4% | -91.5% | 1672.9% | 26.3% | 11.2% | 753.7% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | Sales & Marketing ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|---|---|
| 2022 | $27.3B | $3.6B | $5.0B | $0.0 | $0.0 | $5.7B | $2.1B |
| 2023 | $27.1B | $3.8B | $5.7B | $3.3B | $2.8B | $6.1B | $2.7B |
| 2024 | $28.8B | $3.5B | $5.9B | $3.5B | $2.5B | $6.0B | $2.8B |
| 2025 | $29.4B | $3.5B | $5.8B | $3.5B | $2.2B | $5.7B | $2.8B |
| TTM | $29.4B | $3.5B | $5.8B | $3.5B | $2.2B | $5.7B | $2.8B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | Sales & Marketing Change (%) | G&A Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|---|---|
| 2023 | -0.60 | 7.06 | 14.89 | inf | inf | 6.86 | 28.06 |
| 2024 | 6.04 | -8.44 | 3.31 | 5.53 | -8.71 | -1.02 | 2.75 |
| 2025 | 2.39 | -0.29 | -1.83 | 2.00 | -14.17 | -4.87 | -0.25 |
| TTM | -0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $58,533M |
| 1 | Cash | $7,330M |
| 2 | Total Liabilities | $37,077M |
| 3 | Total Debt | $24,941M |
| 4 | Total Equity | $21,540M |
| 5 | Debt to Equity Ratio | 1.16 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $148.95 | 4.0% | Nicks Growth: 2% Nick's Expected Margin: 15% FINVIZ Growth: 9% |
Nicks: 8 Finviz: 16 |
Nick's: 1.230 | 6.3 | 21.9 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $6.79 EPS | TTM | $55.69 | -62.6% | $108.80 | -27.0% |
| $8.66 EPS | 2026 | $71.03 | -52.3% | $138.77 | -6.8% |
| $9.63 EPS | 2027 | $78.99 | -47.0% | $154.31 | 3.6% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 12.24% | 8.61% | 12.63% | 8.59% | 1.02% | 0.57% | 11.81% | 8.07% | 32.6% | 16.6% |
| 3 Years | 12.24% | 8.61% | 12.63% | 8.59% | 1.02% | 0.57% | 11.81% | 8.07% | 32.6% | 16.6% |
| 5 Years | 12.24% | 8.61% | 12.63% | 8.59% | 1.02% | 0.57% | 11.81% | 8.07% | 32.6% | 16.6% |
| 10 Years | 12.24% | 8.61% | 12.63% | 8.59% | 1.02% | 0.57% | 11.81% | 8.07% | 32.6% | 16.6% |